Literature DB >> 26232929

[18F]fluorodeoxyglucose uptake as a predictor of large joint destruction in patients with rheumatoid arthritis.

Yukio Yonemoto1, Koichi Okamura2, Kimihiko Takeuchi3, Tetsuya Kaneko4, Tsutomu Kobayashi5, Chisa Okura2, Yoshito Tsushima6, Kenji Takagishi2.   

Abstract

The present retrospective study investigated the relationship between [(18)F]fluorodeoxyglucose-positron emission tomography (FDG-PET) findings and subsequent progression of joint destruction on plain X-ray. Nineteen rheumatoid arthritis (RA) patients (59 joints) who underwent FDG-PET and whose joints could be evaluated on plain X-ray 5 years later were included in this retrospective investigation. The relationship between the standardized uptake value (SUV) on FDG-PET and Larsen grade progression on plain X-ray was investigated for each joint. Factors related to progression of joint destruction were also investigated. Joints with advanced joint destruction (Larsen grades IV and V) on X-ray imaging at the time of FDG-PET were excluded. On initial plain X-ray images taken at the time of FDG-PET, a significant correlation was observed between the initial SUV of each joint and the progression of joint destruction 5 years later (R = 0.47, P < 0.01). Significant correlations between the SUV and progression of joint destruction were observed in both load-bearing (R = 0.52, P < 0.01) and non-load-bearing joints (R = 0.52, P < 0.01). On logistic regression analysis, higher SUV and lower prednisolone dose were associated with greater risk of progressive joint destruction (P < 0.05). On receiver operating characteristics curve analysis, the optimum threshold for identifying preceding joint destruction was an SUVmean of 1.33. In RA joints, FDG uptake was seen mostly by inflammatory cells; therefore, FDG uptake reflected joint inflammation. Additionally, the activity seen on FDG-PET might be associated with future radiographic changes in RA patients.

Entities:  

Keywords:  FDG-PET; Joint destruction; Larsen grade; Rheumatoid arthritis; Standardized uptake value

Mesh:

Substances:

Year:  2015        PMID: 26232929     DOI: 10.1007/s00296-015-3331-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  23 in total

1.  Ultrasonography is a potent tool for the prediction of progressive joint destruction during clinical remission of rheumatoid arthritis.

Authors:  Ryusuke Yoshimi; Maasa Hama; Kaoru Takase; Atsushi Ihata; Daiga Kishimoto; Kayo Terauchi; Reikou Watanabe; Takeaki Uehara; Sei Samukawa; Atsuhisa Ueda; Mitsuhiro Takeno; Yoshiaki Ishigatsubo
Journal:  Mod Rheumatol       Date:  2012-07-18       Impact factor: 3.023

2.  F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis.

Authors:  Gerhard W Goerres; Adrian Forster; Daniel Uebelhart; Burkhardt Seifert; Valerie Treyer; Beat Michel; Gustav K von Schulthess; Achim H Kaim
Journal:  Clin Nucl Med       Date:  2006-07       Impact factor: 7.794

3.  (18)F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3.

Authors:  Catherine Beckers; Xavier Jeukens; Clio Ribbens; Béatrice André; Stefaan Marcelis; Philippe Leclercq; Marie-Joëlle Kaiser; Jacqueline Foidart; Roland Hustinx; Michel G Malaise
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-25       Impact factor: 9.236

4.  Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.

Authors:  W E Palmer; D I Rosenthal; O I Schoenberg; A J Fischman; L S Simon; R H Rubin; R P Polisson
Journal:  Radiology       Date:  1995-09       Impact factor: 11.105

5.  Whole-body FDG-PET/CT on rheumatoid arthritis of large joints.

Authors:  Kazuo Kubota; Kimiteru Ito; Miyako Morooka; Takuya Mitsumoto; Kyoko Kurihara; Hiroyuki Yamashita; Yuko Takahashi; Akio Mimori
Journal:  Ann Nucl Med       Date:  2009-10-16       Impact factor: 2.668

6.  Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis.

Authors:  O D Messina; J C Barreira; J R Zanchetta; J A Maldonado-Cocco; C E Bogado; O N Sebastián; D Flores; A M Riopedre; G Redondo; A Lázaro
Journal:  J Rheumatol       Date:  1992-10       Impact factor: 4.666

7.  Analysis of subclinical synovitis detected by ultrasonography and low-field magnetic resonance imaging in patients with rheumatoid arthritis.

Authors:  Hiroshi Ogishima; Hiroto Tsuboi; Naoto Umeda; Masanobu Horikoshi; Yuya Kondo; Makoto Sugihara; Takeshi Suzuki; Isao Matsumoto; Takayuki Sumida
Journal:  Mod Rheumatol       Date:  2014-01       Impact factor: 3.023

8.  Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis.

Authors:  R P Polisson; O I Schoenberg; A Fischman; R Rubin; L S Simon; D Rosenthal; W E Palmer
Journal:  Arthritis Rheum       Date:  1995-06

9.  Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab--preliminary data.

Authors:  Maasa Hama; Takeaki Uehara; Kaoru Takase; Atsushi Ihata; Atsuhisa Ueda; Mitsuhiro Takeno; Kazuya Shizukuishi; Ukihide Tateishi; Yoshiaki Ishigatsubo
Journal:  Rheumatol Int       Date:  2011-02-04       Impact factor: 2.631

10.  Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT.

Authors:  Koichi Okamura; Yukio Yonemoto; Chisa Okura; Tetsuya Higuchi; Yoshito Tsushima; Kenji Takagishi
Journal:  BMC Musculoskelet Disord       Date:  2014-11-22       Impact factor: 2.362

View more
  5 in total

Review 1.  2-deoxy-2[18F]fluoro-D-glucose positron emission tomography-computed tomography in rheumatological diseases.

Authors:  Manil Subesinghe; Shaheel Bhuva; Nikita Arumalla; Andrew Cope; David D'Cruz; Sujith Subesinghe
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

2.  Quantitative Metabolic Volumetric Product on 18Fluorine-2fluoro-2-deoxy-D-glucose-positron Emission Tomography/Computed Tomography in Assessing Treatment Response to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Multiparametric Analysis Integrating American College of Rheumatology/European League Against Rheumatism Criteria.

Authors:  Nandigam Santosh Kumar; Yogesh Shejul; Ramesh Asopa; Sandip Basu
Journal:  World J Nucl Med       Date:  2017 Oct-Dec

3.  Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?

Authors:  Masahiro Tachibana; Yukio Yonemoto; Koichi Okamura; Takahito Suto; Hideo Sakane; Tetsuya Kaneko; Trang Thuy Dam; Chisa Okura; Tsuyoshi Tajika; Yoshito Tsushima; Hirotaka Chikuda
Journal:  Arthritis Res Ther       Date:  2020-07-25       Impact factor: 5.156

4.  Shoulder tenderness was associated with the inflammatory changes on magnetic resonance imaging in patients with rheumatoid arthritis.

Authors:  Satoshi Shinagawa; Koichi Okamura; Yukio Yonemoto; Hitoshi Shitara; Takahito Suto; Hideo Sakane; Trang Thuy Dam; Tsuyoshi Tajika; Yoshito Tsushima; Kenji Takagishi; Hirotaka Chikuda
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

5.  Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?

Authors:  D A M Thuy Trang; Koichi Okamura; Takahito Suto; Hideo Sakane; Yukio Yonemoto; Takahito Nakajima; Yoshito Tsushima; Hirotaka Chikuda
Journal:  Arthritis Res Ther       Date:  2021-08-03       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.